Ganciclovir concentrations in the cerebral extracellular space after valganciclovir treatment; a case study
Inti Peredo, Anders Helldén, Nina Wolmer-Solberg, Anton Pohanka, Giuseppe Stragliotto, Afsar Rahbar, Lars Ståhle, Bo-Michael Bellander, Cecilia Söderberg-Nauclér, Inti Peredo, Anders Helldén, Nina Wolmer-Solberg, Anton Pohanka, Giuseppe Stragliotto, Afsar Rahbar, Lars Ståhle, Bo-Michael Bellander, Cecilia Söderberg-Nauclér
Abstract
Nearly all glioblastomas (GBMs), brain tumours with very poor prognosis, are infected with human cytomegalovirus (CMV). The anti-CMV drug valganciclovir (VGCV) has shown promise as a treatment option for patients with GBM, but its penetration into the central nervous system (CNS) is unknown. Here we describe a patient with GMB receiving VGCV in whom an intracerebral microdialysis catheter was implanted and ganciclovir (GCV) concentrations in brain extracellular fluid (BECF) and serum were monitored. GCV was rapidly absorbed. Cmax values (at 3 h) in serum and BECF were 19.6 and 10.2 µmol/L, T½ values were 3.2 and 4.5 h, and plasma and BECF AUC0-∞ values were 90.7 and 75.9 µmol h/L, respectively. Thus, VGCV treatment results in significant intracerebral levels of GCV that may be sufficient for therapeutic effects. Further studies of this drug in patients with GBM are warranted.
2015 BMJ Publishing Group Ltd.
Figures
Source: PubMed